Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
ExcepGen logo — Solving fundamental problems in drug discovery to create a n...

ExcepGen

Solving fundamental problems in drug discovery to create a new generation of therapeutics.

Founded 2018 United States San Francisco, United States 3 employees Seed Total: $4.18M Biopharma, Biotechnology +2

General Information

Company Name ExcepGen
Founded Year 2018
Location United States San Francisco, United States
Employees 3
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Seed
Business Model B2B, B2D
Revenue Model Licensing, Product Sales, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with ExcepGen. To contact ExcepGen, visit excepgen.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ExcepGen compare?

A PDF of ExcepGen and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ExcepGen soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About ExcepGen

ExcepGen, an early-stage biotechnology startup founded in 2018, is rapidly making its mark in the biopharma and healthcare sectors. Located in San Francisco, United States, the company is devoted to addressing fundamental challenges in drug discovery. With the ambitious slogan "Solving fundamental problems in drug discovery to create a new generation of therapeutics," ExcepGen focuses on pioneering solutions that drive the creation of novel therapeutics.

Recently, ExcepGen secured a $4.00M Seed Round investment on August 24, 2023, indicating robust early-stage traction and investor confidence. The investment was spearheaded by notable investors such as RA Capital Management, Apollo Projects, ZAKA VC, Oxonian Ventures, and the Gravity Fund.

ExcepGen holds significant potential for shaping future biopharmaceutical breakthroughs. Its strong focus on innovation in drug discovery positions it well within the competitive landscape of life sciences.

Business keywords: drug discovery, therapeutics, protein research, venture-backed, early-stage company, R&D, San Francisco-based, biopharmaceuticals, therapeutic development, scientific research, biotech startup, life sciences, diagnostic technology

Services & Products

Development of RNA-based vaccines
Research on mRNA encoded proteins
Creating solutions to modify cellular responses
Production of nucleoside modifications

Target Customers

Pharmaceutical companies Biotech research institutions Healthcare providers Vaccine developers

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round $4.00M 5
RA Capital Management Apollo Projects ZAKA VC
RA Capital Management, Apollo Projects +3
24 Aug 2023
Seed Round $25.00K 1
SV Angel
SV Angel
01 Jul 2020
Seed Round $150.00K 2
Y Combinator Pi Campus
Y Combinator, Pi Campus
18 Mar 2019

Latest News

View All
ZAKA unveils its first fund of €15 million aimed at supporting early stage startups across Europe an... — Eu-startups
ZAKA unveils its first fund of €15 million aimed at supporting early stage startups across Europe and the US
Eu-startups Jul 19, 2024
ZAKA unveils €15M 'Fund I' — Tech
ZAKA unveils €15M 'Fund I'
Tech Jul 19, 2024

ExcepGen Alternatives & Competitors

View All Alternatives
ExcepGen vs
Engine Biosciences
Engine Biosciences Singapore

Deciphering Biological Complexity to Unleash Many Impactful Medicines

34 employees
AI, Biotechnology
ExcepGen vs
DEM Biopharma, Inc.
DEM Biopharma, Inc. United States

Novel Target for Solid Tumors

20 employees
Biotechnology, Life Sciences
ExcepGen vs
Anavo Therapeutics BV
Anavo Therapeutics BV The Netherlands

UNLOCKING THE PHOSPHATASE TARGET CLASS

Seed
24 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About ExcepGen

Solving fundamental problems in drug discovery to create a new generation of therapeutics.
ExcepGen was founded in 2018.
ExcepGen is headquartered in San Francisco, United States.
ExcepGen operates in Biopharma, Biotechnology, Health Care and Life Sciences. Its work centres on drug discovery, therapeutics, protein research and venture-backed. Its customers include Pharmaceutical companies, Biotech research institutions and Healthcare providers.
ExcepGen has a B2B and B2D business model. Its revenue comes from Licensing, Product Sales and Service Fee.
ExcepGen has approximately 3 employees.
ExcepGen has completed 3 funding rounds, raising a total of $4.18M. The latest funding stage is Seed.
ExcepGen offers: Development of RNA-based vaccines, Research on mRNA encoded proteins, Creating solutions to modify cellular responses, Production of nucleoside modifications.
Top alternatives and competitors to ExcepGen include Engine Biosciences, DEM Biopharma, Inc., Anavo Therapeutics BV, Sitryx, Vivace Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ExcepGen and Engine Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ExcepGen, https://bouncewatch.com/company/excepgen, updated 12 April 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout